Oct4 and Nanog are two embryonic stem (ES) cell-specific transcription factors that play critical roles in the maintenance of ES cell pluripotency. In this study, we investigated the effects of Oct4 and Nanog expression on the differentiation state of myogenic cells, which is sustained by a strong positive feedback loop. Oct4 and Nanog, either independently or simultaneously, were overexpressed in C2C12 myoblasts, and the expression of myogenic lineage-specific genes and terminal differentiation was observed by RT-PCR. Overexpression of Oct4 in C2C12 cultures repressed, while exogenous Nanog did not significantly alter C2C12 terminal differentiation. The expression of Pax7 was reduced in all Oct4-overexpressing myoblasts, and we identified a major Oct4-binding site in the Pax7 promoter. Simultaneous expression of Oct4 and Nanog in myoblasts inhibited the formation of myotubes, concomitant with a reduction in the endogenous levels of hallmark myogenic markers. Furthermore, overexpression of Oct4 and Nanog induced the expression of their endogenous counterparts along with the expression of Sox2. Using mammalian two-hybrid assays, we confirmed that Oct4 functions as a transcriptional repressor whereas Nanog functions as a transcriptional activator during muscle terminal differentiation. Importantly, in nonobese diabetic (NOD) severe combined immunodeficiency (SCID) mice, the pluripotency of C2C12 cells was conferred by overexpression of Oct4 and Nanog. These results suggest that Oct4 in cooperation with Nanog strongly suppresses the myogenic differentiation program and promotes pluripotency in myoblasts.
Pax7; pluripotency; differentiation; stem cell SKELETAL MUSCLE CELLS are derived from axial somitic cells during early embryogenesis. Presomitic cells are specified by signals from the notochord and neural tube to induce them to express Pax3 and Pax7 (10, 19) and thus become the stem cells of the myogenic lineage. Some of the Pax3 and Pax7-expressing myogenic stem cells will be further induced by axial signals to express a basic helix-loop-helix transcription factor, either MyoD, Myf5, or myogenic regulatory factor 4 (MRF4) (7) . Once expressed, MyoD and Myf5 activate their own expression to establish a positive feedback loop that restricts these cells, called myoblasts, in the myogenic lineage (9, 22) . Myoblasts are committed to myogenic lineage only and ultimately become terminally differentiated multinucleated myotubes, which are the basic building elements of skeletal muscle.
Terminal differentiation of myogenic lineage is dictated by the function of MRFs, including MyoD, Myf5, myogenin, and MRF4. Overexpression of any one of these MRFs in several nonmyogenic cells can induce their trans-differentiation into myogenic lineage (8) . MRFs can activate the expression of another family of transcription factors, myocyte enhancer factor 2 (MEF2), to commit myoblasts to terminal differentiation (35) . Together, MRFs and MEF2 proteins regulate the differentiation of myoblasts into multinucleated myotubes by activating muscle-specific contractile genes and genes that promote cell-cycle exit, such as p21 cip1 and p27
kip1
. It is well accepted that normal myogenesis is irreversible in vivo due to the positive feedback loop of MRFs. However, some researchers found that multinucleated myotubes could be reversed back to mononucleated myoblasts if antimyogenesis factors, such as Msx-1, were overexpressed (16) . These findings suggest that it is possible to manipulate the differentiation state of myogenic cells.
In recent years, two stem cell-specific transcription factors, Oct4 and Nanog, were identified and found to be essentially required for the maintenance of embryonic stem (ES) cell pluripotency (5, 13) . Oct4 is a POU domain transcription factor (also called Oct3 and Pou5f1) expressed exclusively in blastomeres, pluripotent early embryo cells, and the germ cell lineage (17, 21, 23) . It has been shown that the production of pluripotent stem cells in the mammalian embryo depends critically on the function of Oct4 (14) .
The requirement of leukemia inhibitory factor (LIF) for the maintenance of Oct4-expressing ES cells led to the discovery of Nanog [also called early embryonic specific NK (ENK)] (31), which can confer ES cells self-renewal and pluripotency (5, 13) . Deletion of Nanog triggers differentiation of ES cells into parietal/visceral endoderm, confirming its role in the second embryonic differentiation event (5) . During cell fusion experiments, Nanog has been proved to promote transfer of pluripotency (25) . However, Nanog overexpression cannot reverse the differentiation program induced in ES cells by Oct4 downregulation. They also found that Nanog is expressed in Oct4-deficient embryos (5). Therefore, it seems that Oct4 and Nanog work in concert to sustain stem cell pluripotency and self-renewal (4) .
Recently, three groups have reported that both mouse and human somatic cells can be induced to become pluripotent stem cells (iPS cells) by overexpressing defined factors, including Oct4, Nanog, Sox2, Klf4, and c-Myc or LIN28 (18, 27, 28, 32, 34) . These iPS cells have been demonstrated to be competent at forming most tissues and are germ-line competent when Nanog is overexpressed. C2C12 is a well-defined myoblast cell line that expresses the hallmark myogenic determination factors typical of a predifferentiated myogenic cell. C2C12 cells can be induced to differentiate to myotubes by the withdrawal of serum from the media and are sustained in this state by a strong positive feedback loop (3, 29) . It is of interest to know whether overexpression of Oct4, Nanog, Sox2, Klf4, and c-M or LIN28 can alter the differentiation potency of C2C12 myoblasts.
In this study, we investigated whether the overexpression of Oct4 and Nanog can inhibit or reverse the C2C12 differentiated state and whether these factors can induce pluripotency in vitro. Overexpression of Oct4 in C2C12 myoblasts significantly reduced the fusion index because only 10% of the nuclei were incorporated into myotubes, while exogenous expression of Nanog did not affect C2C12 terminal differentiation to a significant extent. Myoblasts simultaneously overexpressing Oct4 and Nanog formed barely detectable myotubes (fusion index ϭ 0.016%), and their expression of MRFs and Mef2C was significantly reduced after serum withdrawal. Although Oct4 alone failed to abrogate terminal differentiation, the expression level of Pax7 in all Oct4-overexpressed stable clones was significantly reduced. We further identified that Oct4 repressed the expression of Pax7 by direct targeting an Octamer-binding site on its promoter. Our results suggest that Oct4 alone can repress the expression of a subset of myogenic genes and that it requires the cooperation of Nanog to fully suppress myogenic program in myoblasts.
MATERIALS AND METHODS
Plasmids. pPyCAGIP-Nanog was a generous gift from Dr. Ian Chamber (University of Edinburgh, Edinburgh, UK). To make retrovirus expressing Nanog, the cDNA of Nanog was released from pPyCAGIP-Nanog by XbaI and NotI digestion and then blunted by Klenow reaction before inserted into blunted EcoRI site of pMSCVneoEB vector. Oct4 cDNA was amplified from P19 cells by RT-PCR and inserted into blunted XhoI site of pMSCV-neoEB and pPyCAGIP vectors. Pax7-3.8k-luc was created by inserting PCR amplified genomic fragment (Ϫ3880ϳϩ21) into SmaI site of pGL3-basic vector. Genomic fragment corresponding to region Ϫ5001ϳϪ3104 was PCR amplified and digested with SacI before inserted into the same site in Pax7-3.8k-luc to create Pax7-5.0k-luc reporter construct. All PCR cloned constructs were sequenced to ensure their sequence integrity.
Cell culture and transient transfection. Proliferating C2C12 cells and C3H10T1/2 cells were kept in DMEM supplemented with 20% and 10% fetal calf serum (FCS), respectively. To induce C2C12 cells to differentiate, confluent myoblast culture medium was changed to DMEM containing 2% horse serum to reduce the mitogen concentration in the medium. C2C12 cells normally started differentiating 48 -72 h after the serum withdrawal.
For transient transfection, aliquots of plasmid DNA were mixed together in 1ϫ HEPES buffer (20 mM HEPES at pH 7.0, 187 mM NaCl, 5 mM KCl, 0.7 mM Na 2HPO4, and 5.5 mM dextrose) in 5 ml test tubes, and then a mixture of liposomes containing DOTAP and DOSPER (Boehringer Mannheim) in 1ϫ HEPES buffer was added to the DNA mixture and incubated at room temperature for 10 -15 min to allow DNA and liposome complex to form. Aliquots of culture medium were added to each tube and mixed with several inversions. Medium containing the DNA-liposome complex in each tube was transferred to cells grown in 12-well dishes in triplicate, and the transfection was allowed to proceed overnight before the medium was replaced by fresh medium. Cells were harvested 24 -48 h after transfection with repeated freeze and thaw cycles in lysis buffer. Aliquots of total lysate (100 l) were injected into a Bio-Tek Clarity 2 luminometer to determine their luciferase activity. All luciferase (firefly) activities were normalized to that of PRL-TK-(Renilla) reporter vector (1 g), which was included in each reaction to serve as a transfection efficiency control.
Manufacture of retrovirus expressing Oct4 and Nanog and their infection of C2C12 myoblast. The cDNA of both Oct4 and Nanog were cloned into the XhoI site of pMSCV-neoEB retroviral vector for making a retrovirus carrying either Oct4 or Nanog cDNA (pMSCVneoEB-Oct4, pMSCV-neoEB-Nanog). After their successful construction, these retroviral vectors were transfected into GPϩE86 package cells (12) , a cell line carrying viral genes of the groupassociated antigens, reverse transcriptase, and envelop (env) proteins, to generate infectious retrovirus. Transfected GPϩE86 cells were then selected with G418 (400 g/ml) for at least 2 wk to obtain polyclonal population that stably express either Oct4 or Nanog. The culture medium (8 ml) containing infectious retrovirus was collected and centrifuged at 2,000 rpm for 10 min before transferred to C2C12 myoblasts to replace their culture medium. Infection was allowed to proceed for 2-3 days with fresh medium transferred from stable GPϩE86 cells every day to increase the infection ratio. Successfully infected cells would carry neomycin-resistant gene, so they can be selected against by the antibiotic, G418. Selection was allowed to proceed for 2-3 wk, and then RNA and protein were isolated from stably infected cells to verify the expression of Oct4 and Nanog by both RT-PCR and Western blot assays.
Simultaneous expression of Oct4 and Nanog in C2C12. To generate myoblasts expressing Oct4 and Nanog at the same time, the cDNA of both Oct4 and Nanog was cloned into the XhoI site of pPYCAGIP vector, a generous gift from Dr. Ian Chamber (University of Edinburgh), to generate pPYCAGIP-Oct4 and pPYCAGIP-Nanog vector, respectively. Oct4 or Nanog inserted into pPYCAGIP vector would be expressed in a bicistronic transcript driven by actin promoter. The downstream cistron encodes puromycin-resistant gene and whose translation is controlled by an internal ribosome entry site (IRES) located between these two cistrons. Therefore, all puromycin-resistant clones would express the inserted gene at the same time. To express Oct4 and Nanog in C2C12 myoblasts at the same time, retrovirus transduced C2C12 myoblasts expressing either Oct4 or Nanog were transfected with either pPYCAGIP-Oct4 or pPYCAGIP-Nanog and selected against G418 (400 g/ml) and puromycin (3 g/ml) for at least 2-3 wk. Then, total RNA and protein were isolated and examined with RT-PCR and Western blot to confirm exogenous expression of Oct4 and Nanog.
Establishment of C2C12 stable clones of Pax7-5.0k-luc. Pax7 5.0 K promoter was PCR amplified and inserted into the blunted XhoI site of a pGL3-basic derived reporter vector named pSTABLE, in which a neomycin-resistant gene expression cassette was inserted into the BamH I site downstream to the luciferase expression cassette. C2C12 cells were transfected with pSTABLE-Pax7-5.0k-luc and selected with 800 g/ml of G418 for 2-3 wk before monoclones were picked up and transferred to a 24-well plate. The luciferase activity of each monoclone was determined, and three of positive clones (clone nos. 7, 17, and 22) were further transfected with pPyCAG and pPyCAG-Oct4 independently. After selection with puromycin (3 g/ml) for 2-3 wk, these monoclonal cells were plated into 12-well plates and with their luciferase activity determined in hexaplicate and normalized to their protein amount.
Reverse transcription and polymerase chain reaction. Total RNA was extracted from the myoblasts and myotubes using TRIzol according to the supplier's instruction. Then, the first strand of cDNA was synthesized using the Superscript III kit for RT-PCR. Briefly, total RNA was denatured at 65°C for 5 min in the presence of 0.5 g oligo(dT) and 1 mM dNTP. After chilling on ice for at least 1 min, reverse transcription was allowed to proceed at 25°C for 5 min in the presence of 1ϫ first-strand buffer, 5 mM DTT, and 40 units of RNase inhibitor. Then, the reaction was allowed to proceed at 50°C for another 60 min. Reaction was inactivated by heating inactivation at 70°C for 10 min.
PCR reactions were performed in a 10-l reaction mixture containing 5 M forward and reverse primers, Taq DNA polymerase (5 units), and 0.5% DMSO to increase specificity of amplification. The reaction was performed with preliminary denaturation for 5 min at 95°C, followed by 22-35 cycles of denaturation at 95°C for 15 s, and annealing/extension at 60°C for 1 min. For comparison of expression levels among a set of samples, Gadph and ribosomal binding protein (m36b4) were served as input controls and whose PCR signals were equalized by adjusting cDNA input of each sample. Then, the other genes were amplified according to the adjusted cDNA input, which was equivalent to ϳ25 ng of total RNA. A tube containing an equivalent amount of total RNA was used as reverse transciptase control and amplified in the same PCR reaction. Only samples shown to be free of genomic contamination were further analyzed. Minimal number of PCR cycle was used to avoid saturation of PCR. The PCR reaction for each gene was repeated at least twice and with similar results obtained. The primer sets used for each gene are listed in Supplemental Table 1 (supplemental material for this article is available online at the American Journal of Physiology: Cell Physiology website). To determine the expression of endogenous Nanog and Oct4, a special primer located at the untranslated region, which was not included in the ectopic genes, was used in the PCR reaction, so only transcripts derived from endogenous genes can be amplified.
Quantitative real-time RT-PCR. Total RNA extraction and reverse transcription were performed as described in RT-PCR. Real-time quantitative PCR was performed in a 25-l reaction mixture containing 5 M forward/reverse primers, 1ϫ SYBR GREEN reaction mix (Applied Biosystems, Werrington, UK), and various amounts of template. The reaction was performed with preliminary denature for 10 min at 95°C to activate Taq DNA polymerase, followed by 40 cycles of denature at 95°C for 15 s, and annealing/extension at 63°C for 1 min. Different amounts of template were used in the same reaction to make sure the linear amplification of PCR products. Gapdh was used as internal control amplified in the same PCR assay. The primer sets used were the same as those used in traditional RT-PCR. All reactions were performed in ABI 7300 sequence detection system.
Electrophoretic mobility shift assay. 32 P-labeled oligonucleotide corresponding to the Octamer 4.7k site in the Pax7 gene promoter was made by end-labeling reaction mediated by polynucleotide kinase (New England Biolabs).
32 P-labeled probe was further purified by gel purification in 15% acrylamide buffered by 1ϫ Tris-borate-EDTA (TBE) buffer. In vitro transcribed and translated (TNT kit, Promega) Oct4 protein and nuclear extract (5 g) from P19 cells were used to bind 32 P-Labeled oligonucleotide probe in 20 l binding buffer (25 mM HEPES at pH 7.4, 5 mM MgCl2, 4 mM EDTA, 2 mM DTT, 110 mM NaCl, 5 g/ml BSA, and 0.8% Ficoll) at room temperature for 30 min. Protein and DNA complexes were resolved on a 5% acrylamide low ionic gel containing 5% glycerol at 4°C for at least 3.5 h. Signals on the gels were viewed by autoradiography. Antibody (0.1 g) against Oct4 was included in the binding reaction to verify the identity of factors containing in the retarded bands on the gel. The specificity of DNA and protein binding was tested by adding 10-100ϫ amount of unlabeled cold Oct4-binding site as specific competitor or DNA corresponding to GADPH coding region as nonspecific competitor.
Glutathione S-transferase pulldown assay. Glutathione S-transferase (GST) and GST-fusion proteins were expressed in Escherichia coli strain BL21 and purified using glutathione-agarose (Pharmacia) affinity chromatography. GST-Nanog fusion proteins were analyzed on 10% SDS-PAGE gels to examine their integrity and to normalize the protein levels. 35 S-methionine/cystein-labeled proteins were produced by employing a TNT-coupled system (Promega). In vitro binding assays were performed with 3-6 l 35 S-labeled proteins [silencing mediator for retinoic acid and thyroid hormone receptor (SMRT) and Oct4] and 200 -300 ng GST-Nanog proteins adsorbed on the glutathione-agarose beads in 500 l HEMG buffer [40 mM HEPES at pH 7.8, 0.2 mM EDTA, 100 mM KCl, 0.1% Nonidet P-40 (NP40), 1.5 mM DTT, and 10% glycerol] freshly supplemented with 1% BSA and protease inhibitors. The binding reaction was allowed to proceed for 2 h at room temperature or overnight at 4°C with gentle rocking. The affinity beads were collected by centrifugation and washed with 1 ml HEMG buffer. The wash step was repeated three times, and the beads were dried before the addition of 2ϫ Laemmli sample buffer to elute bound proteins. Eluted proteins were resolved on 10% SDS-PAGE gels, and signals were visualized with autoradiography.
Mammalian two-hybrid assay. C2C12 cells grown in 12-well plates at 60 -70% confluence were transfected with 0.67 g G5E1b-Luc reporter, 0.3 g of GAL chimeras (gal-Oct4 or -Nanog), and 0.3 g of VP16 chimeras (vp16-Oct4, -Nanog) in the presence and absence of corepressor in 300 l of serum-free DMEM by Lipofectamine (Invitrogen)-mediated method. Transfection was allowed to precede for 16 -24 h; the medium was then replaced with normal growth medium, and cells were harvested 24 -48 h after transfection for determination of their luciferase activity. Each experiment was performed in triplicate and repeated at least three times to overcome the variability inherent in transfection experiments. GAL and VP16 chimeras were generated by fusing full-length coding region of Oct4 and Nanog with GAL4 DNA-binding domain (GAL4DBD) and VP16 activation domain, respectively.
Statistical analyses. All transfection experiments were performed in triplicate and repeated at least three times, with similar results observed. The average/mean of each triplicate set was used to represent the value of that experiment. Results from independent experiments were pooled, and the difference between various treatments was examined with Student's t-test. All tests were two-sided, and a probability value of Ͻ0.05 was considered statistically significant. For real-time PCR, each assay was performed in duplicate of two different inputs to ensure linear PCR amplification. Results from independent assays were pooled, and the difference between control cells and stable clones overexpressing Oct4 and Nanog was examined with Student's t-test.
Western blot analysis. Myoblasts grown on 10-cm Petri dishes were trypsinized and then lysed with 150 l RIPA buffer (20 mM Tris, 150 mM NaCl, 1% deoxycholate, 0.1% SDS, and 1% Triton X-100, pH 7.8) supplemented with protease inhibitors to extract total protein. After centrifugation at 12,500 rpm for 30 min at 4°C, the concentration of the protein in the supernatant was determined by BCA reagent. For extraction of nuclear protein, cells were swelled in hypotonic solution and then lysed with repeated freeze-thaw cycles. Nuclei were collected by centrifugation at 2,000 rpm and later extracted with extraction buffer (20 mM Tris, 400 mM KCl, 1% glycerol, 2 mM MgCl 2, 1 mM DTT, pH 8.0). Nuclear protein concentration was determined by Bradford assay. Aliquots of total lysate (100 g) or nuclear extract (50 g) were run on 10% SDS-PAGE gels before blotted onto polyvinylidene difluoride (PVDF) membrane (Pall FluoroTrans W membrane, PALL) by a semi-dry blotter at 160 mA for at least 16 h. The PVDF membranes were extensively washed with 1ϫ PBS containing 0.5% Tween 20 (PBST) before blocked by 5% skimmed milk in PBST. Primary antibodies against Oct4 (no. 611202, BD Pharmingen) and Nanog (ab21603-100, Abcam; Cambridge, UK) were diluted 1:1,000 in blocking solution (5% milk in PBST) and incubated with the blot at 4°C for overnight. After several washes with PBST, horseradish peroxidase (HRP)-conjugated secondary antibody (1:1,000 dilution) was added and incubated at room temperature for 1 h. The signals was detected by a chemiluminescence kit (Amersham Pharmacia Biotech) and visualized on X-ray films (Super RX, Fuji Medical X-film; Tokyo, Japan). For detection of Laminin B1 and GAPDH internal control, all the blots were stripped by incubating with stripping buffer (2% SDS, 100 mM ␤-mercaptoethanol, and 50 mM Tris, pH 6.8) at 50°C for 30 min.
After extensive wash in PBST, the blots were blocked and incubated with either Laminin B1 (ab16048, Abcam) or GAPDH antibody (1:500 dilution; Sc-815, Santa Cruz) and HRP-conjugated secondary antibody as described above.
Assay for teratoma formation. C2C12-retro-Py and C2C12-Oct4-Py-Nanog cells were trypsinized and resuspended at 1 ϫ 10 6 cells/ml in DMEM containing 20% FCS. Then, 500 l of cell suspension was injected subcutaneously into the dorsal flank of nonobese diabetic (NOD) severe combined immunodeficiency (SCID) mice. Eight weeks after the injection, tumors were surgically removed from the mice and fixed in PBS containing 4% paraformaldehyde. These samples were subsequently dehydrated and embedded in paraffin. Paraffin-embedded tissue blocks were sectioned at 2-to 5-m thickness, and sections were stained with hematoxylin and eosin. The animal experimental procedures were approved by the Animal Ethics Committee at National Central University.
Chromatin immunoprecipitation assay. C2C12-Oct4-Py-Nanog cells were washed several times with PBS before fixed in 1% formaldehyde for 20 min at 25°C. Then, cells were washed two times with cold PBS and followed by incubation in PBS containing 125 mM glycine for 15 min before scratched off in PBS containing 2 mM EDTA. Cells were spun at 2,000 rpm for 5 min at 4°C, and then washed with ice-cold PBS twice. The pellet was resuspended in 250 l lysis buffer (50 mM Tris ⅐ HCl, 150 mM NaCl, pH 8.1, 0.1% SDS, 1% Triton X-100, and 1ϫ protease inhibitor) and sonicated five times at 30-s, 140-to 150-W pulse with 30-s rest intervals. The lysate was spun at 13,000 rpm for 10 min at 4°C to clear the solution, and the supernatant was transferred to a new tube. Then, protein A/G agarose (80 l) was added into the supernatant and incubated at 4°C for 20 min before being spun at 6,000 rpm for 5-10 min at 4°C to clear the solution. The supernatant was transferred to a new tube into which 1 g specific antibody was added. The binding was allowed to proceed at 4°C for overnight. Protein A/G agarose (80 l) was then added and incubated for another hour to capture the immune complex. The beads were collected and washed four times in lysis buffer for 10 min and then washed once in LiCl buffer (0.25 M LiCl, 1% NP-40, 1% deoxycholate, 1 mM EDTA, and 10 mM Tris ⅐ HCl, pH 8.1) and twice in 1ϫ Tris-EDTA buffer (pH 8.1) for 5 min. The immune complex was eluted twice with 100 l elution buffer (1% SDS, 0.1 M NaHCO3, pH 8.0), and the eluate was heated at 65°C overnight to reverse the cross-linking. The eluted DNA was purified with a PCR purification kit before being amplified with primers targeting Nanog promoter, Pax7 4.7K Octamer, and Pax7 exon 9.
RESULTS

Endogenous expression levels of Oct4 and Nanog in myogenic cells.
To examine the effects of Oct 4 and/or Nanog overexpression in myogenic cells we first determined endogenous expression level of Oct4 and Nanog by semi-quantitative RT-PCR. We found that both Oct4 and Nanog were highly expressed in P19 embryonic carcinoma cells, but only weakly expressed in Sol8 and C2C12 myoblasts (Fig. 1) . Their expression was not detectable in C3H10T1/2 fibroblasts (at 35 PCR cycle). Therefore, the well-characterized C2C12 cell line is a suitable candidate for the examination of Nanog and Oct4 Fig. 1 . The expression of Oct4 and Nanog in myogenic cells. The expression of Nanog and Oct4 in Sol8 and C2C12 myoblasts, 10T1/2 fibroblasts, and P19 embryonic carcinoma cells was examined by semiquantitative RT-PCR. Reverse-transcribed cDNA derived from total RNA (25 ng) was used as PCR template. The amount of cDNA input was adjusted to equalize the expression level of Gapdh; then, the same amount of cDNA was used as template for amplifying Oct4 and Nanog transcripts. The number of PCR cycles used was 35 for Oct4 and Nanog and 25 for Gapdh. The numbers at right represent the size of amplicons in base pairs. NTC, no template control. Fig. 2 . The transactivational activity of Oct4 and Nanog in myogenic cells. The transcriptional activity of Oct4 and Nanog as well as their interactions was examined in the mammalian two-hybrid assays. A: G5E1b-Luc reporter was cotransfected with vectors expressing either Gal-Nanog or Gal-Oct4 in the presence or absence of VP16-Oct4 and VP16-Nanog expression vectors into C2C12 myoblasts. Cells were harvested 24 h after transfection for luciferase assay. All luciferase activity was normalized to that of empty vector control [Gal-DNA-binding domain (DBD) and VP16 only], which was arbitrarily set as 1-fold of activation. The longitudinal coordinate is shown in logarithmic scale. Results shown here are means Ϯ SD. B: Nanog interacts with Oct4 in vitro. Glutathione S-transferase (GST) or GST-Nanog fusion protein was used to pull down 35 S-labeled Oct4 and silencing mediator for retinoic acid and thyroid hormone receptor (SMRT) proteins in 500 l HEMG buffer at 4°C. After 5 washes in HEMG buffer, proteins were eluted by SDS sample buffer and viewed by autoradiography. *P Ͻ 0.05 and **P Ͻ0.01 compared with Gal-Nanog/Vp16; #P Ͻ 0.05 and ##P Ͻ 0.01 compared with Gal-Oct4/Vp16. overexpression on terminal differentiation and the transcriptional repression of myogenic determination genes.
Transcriptional activity of Nanog and Oct4 in myogenic cells. Since Nanog is a recently identified transcription factor, its function in the transcriptional regulation of target genes, especially in myogenic stem cells, remains largely unknown. Full-length Nanog was fused to the GAL4DBD and cotransfected into C2C12 cells along with the reporter construct G5E1B-Luc, containing five GAL4 binding sites. We found that Nanog functioned as a transcriptional activator regardless of the cell line transfected ( Fig. 2A and data not shown) . To establish whether Nanog functions as a monomer or dimer, we made use of a Gal4DBD-Vp16TAD (Vp16 transactivation domain) twin hybrid assays. Interactions between Gal4DBD- Fig. 3 . Effects of Oct4 and Nanog overexpression on terminal myogenic differentiation. C2C12 were infected with Oct4-expressing retrovirus first and then stably transfected with pPyCAGIP-Nanog to create Oct4 and Nanog simultaneously overexpressed clones. Expression levels of ectopic Oct4 and Nanog in these stable clones were detected by semiquantitative RT-PCR (A) and Western blot analysis (B). Reverse-transcribed cDNA derived from total RNA (25 ng) was used as PCR template to amplify the coding sequence of Oct4 and Nanog. Total RNA (25 ng) was also used as PCR template for reactions serving as a control for genomic DNA contamination, and no PCR product was detected in these reactions (data not shown). The expression level of Gapdh served as input control. The number of PCR cycles used was 35 for Oct4 and Nanog and 22 for Gapdh. Py, pPyCAGIP vector. Nuclear extracts (30 g) were used for the detection of Oct4 and Nanog protein, and Lamin B1 served as loading control. C: C2C12 stable clones were allowed to grow to confluence in growth medium and were then induced to differentiate by changing to differentiation medium. The culture medium was changed every 48 h, and cells were photographed and harvested 5 days after induction for isolation of total RNA. A different set of cells was fixed, permeabilized, and stained with myosin heavy chain antibody and hematoxylin to visualize myotubes and their nuclei. The original magnification was ϫ100. Total nuclei and those in myotubes were counted in 4 -6 different photographed fields to calculate their fusion index (nuclei in myotube/total nuclei). D: fusion indexes of the stable clones. All results are representative of at least two independent experiments. Fusion indexes shown here are means Ϯ SD of two independent experiments. **P Ͻ 0.01 as compared with retrovirus (retro)-control.
Nanog and Vp16TAD-Nanog were strong and consistent, suggesting that Nanog functions as a homodimer.
In contrast, Oct4 functioned as a transcriptional repressor as determined by the Gal4 assay system. We observed a weak but significant interaction between Gal4DBD-Oct4 and Vp16TAD-Oct4, whereas Gal4DBD-Nanog and Vp16TAD-Oct4 showed a strong and significant interaction (Fig. 2A) . We confirmed the Oct4 and Nanog interaction in vitro using a pulldown assay (Fig. 2B, lane 5) . These results suggest that Nanog and Oct4 function in myogenic precursor cells as a protein complex to regulate target gene expression.
Stable expression of Oct4 and Nanog in C2C12 myoblasts. To overexpress Nanog and Oct4 simultaneously in C2C12 myoblasts, a two-step approach was used. First, C2C12 myoblasts were transduced with retroviruses expressing Oct4 to establish C2C12-Oct4 stable clones that constitutively overexpressed Oct4. Subsequently, C2C12-Oct4 cells were transfected with pPYCAGIP-Nanog vector and selected against puromycin for at least 2-3 wk. Nanog and the puromycinresistant gene were expressed in a bicistronic transcript, and the expression of the latter was controlled by an internal ribosomal binding site (IRES). Therefore, all puromycin-resistant clones also express Nanog. The expression of Oct4 and Nanog in these stable clones was abundant and stable as examined by RT-PCR (Fig. 3A) and Western blot analysis (Fig.  3B ). All stable clones used here are polyclonal.
Myogenic differentiation of C2C12 myoblasts overexpressing Oct4 and Nanog. C2C12 myoblasts are very sensitive to contact inhibition; therefore most of them stop proliferating when reaching confluency. Confluent C2C12 myoblasts (CMB) then can be induced to undergo terminal differentiation by replacing growth factor-rich media (20% FCS) with growth factor-poor media (2% horse serum). Terminal differentiation was not affected by overexpression of Nanog, and the fusion index of C2C12-Nanog cells was similar to that of the control cells (Fig. 3,  C and D) . In contrast, C2C12-Oct4 cells differentiated relatively poorer than control cells. Quantification of the fusion index showed a drop to around 11% of the control cells (Fig. 3, C and  D) . In addition, the myotubes formed were thinner, contained fewer nuclei, and were less branched (Fig. 3C) .
Although Nanog alone had little effect on myogenesis, its coexpression with Oct4 enhanced Oct4-mediated myogenic repression. Five days after the induction of differentiation, C2C12-Oct4-Py-Nanog cells formed barely detectable myotubes with a fusion index of 0.0016% (Fig. 3B) . In addition, prolonged culture in differentiation medium did not lead to the formation of myotubes (data not shown). These results suggest that Oct4 and Nanog cooperate to repress myogenic terminal differentiation.
Gene expression pattern of C2C12 stable clones overexpressing Oct4 and Nanog. To unravel the mechanisms of myogenic repression caused by Oct4 and Nanog coexpression, we set out to analyze the gene expression pattern of these stable clones. The expression patterns of MRFs, myogenic stem cell factors, and ES-specific factors in C2C12 stable clones were examined by traditional and quantitative real-time RT-PCR (Fig. 4) . In confluent myoblasts (Fig. 4, A  and C) , overexpression of Nanog significantly reduced the expression of Myogenin and Sca-1 but had weak or no effect on that of the other genes. Overexpression of Oct4 reduced the expression of all myogenic factors studied, and their downregulation was further enhanced by the coexpression of Nanog. On the contrary, the expression of Hoxc10, CD34, and MNF was enhanced by Oct4. Pax7, along with Pax3, is a major factor regulating myogenic stem cell property during embryogenesis and adult life. Pax7-knockout mice are devoid of satellite cells, the major myogenic stem cells present in adult muscle. Here, we found that Pax7 expression was abolished wherever Oct4 was expressed (Fig. 4 , A and C). Since Pax7 also plays an important role in the lineage determination of neural tube derived cells, its downregulation in C2C12-Oct4 cells suggests that repression of its expression during early embryogenesis may represent a major step in the maintenance of pluripotent stem cells.
The expression of myogenin and Mef2C in cells kept in differentiation media for 5 days was significantly enhanced in most clones as compared with cells of CMB stage. However, their expression was significantly repressed in C2C12-Oct4-Py-Nanog (Fig. 4, B and D) , and thus explained at least in part why these cells failed to form myotubes. Significant reduction in the expression of MyoD, Mrf4, Myf5, Pax7, and M-cadherin was observed in Oct4 and Nanog overexpressing clones. However, a residual amount of Myf5 expression was consistently detected in all stable clones. Although the expression of Pax3 in C2C12 was relatively low (detectable only at 40 PCR cycles), its expression was significantly increased in C2C12-Oct4-PyNanog cells. The expressions of the hematopoietic stem cell marker genes Sca1 and CD34 were both significantly enhanced in C2C12-Oct4-Py-Nanog cells (Fig. 4, B and D) .
Oct4 and Nanog play critical roles in the maintenance of ES cell pluripotency; therefore we next examined their expression as well as the expression of other ES cell-specific genes in our stable cell lines. Endogenous Nanog was weakly expressed in C2C12 myoblasts, and its expression in cells of CMB stage was not affected by the expression of ectopic Oct4 and Nanog. However, endogenous Nanog expression was increased in Fig. 4 . Effects of Oct4 and Nanog overexpression on the expression of myogenic and stem cell-specific genes. The expression level of myogenic and stem cell-specific genes in control and in Oct4 and Nanog overexpressed C2C12 stable clones at confluent myoblast (CMB; A and C) and myotube (MT; B and D) stages was determined by semiquantitative (A and B) and real-time (C and D) RT-PCR. For the amplification of each gene, PCR was started with cDNA template equivalent to 25 ng of total RNA, and the thermal cycle was allowed to proceed through 30 -35 cycles, except for m36b4 and Gapdh genes, which served as the internal controls and were amplified for only 22 cycles to prevent saturation of PCR product. The number of PCR cycles used for Pax3 was 38. All primer sets were designed to cross at least one intron so that the amplicons of their genomic DNA targets are significantly different in size from that of their cDNA targets. PCR reactions using equivalent amount of total RNA or no template control (lane N) were run simultaneously to examine the degree of genomic DNA contamination. Only samples without detectable genomic DNA contamination were further analyzed. The sequences of the primer sets used for each gene are listed in Supplemental Table 1 . For Oct4 and Nanog, only endogenous transcripts (endo) were detected here. C and D: gene expression level of cells at CMB and MT stages was also examined by real-time PCR. The expression level of retro-control was set as 1 and compared with that of Oct4 and Nanog stable clones. Genes repressed by Oct4 and Nanog are shown at top, and those activated by Oct4 and Nanog are shown at bottom. Endogenous Nanog, Oct4, and Sox expression was not examined by real-time PCR due to primer dimmer problem. ES, embryonic stem; HSC, hematopoietic stem cells; MEF2C, myocyte enhancer factor 2C; MRF4, myogenic regulatory factor 4. *P Ͻ 0.05 and **P Ͻ 0.01 as compared with retro-control; , undetectable.
C2C12-Nanog and C2C12-Oct4-Py-Nanog cells at the myotube (MT) stage.
Endogenous Oct4 expression was not detectable in cells at the CMB stage but was weakly detectable in cells at the MT stage, which was slightly increased when both Oct4 and Nanog were overexpressed. Sox2 expression was induced by Nanog in confluent myoblasts and in cells at the MT stage. Overexpression of both Nanog and Oct4 further enhanced expression of Sox2, however, only in cells of the MT stage. Klf4 was abundantly expressed in all stable clones, and its expression was slightly enhanced by Oct4 (Fig. 4C) . These results suggest that overexpression of Oct4 and Nanog blocks myogenic differentiation by both repressing MRF expression and inducing ES cell-specific gene expression.
Oct4 directly regulates Pax7 expression. Pax7 plays important roles in the regulation of myogenic determination, and its expression is repressed to undetectable levels in C2C12 overexpressing Oct4. To test whether Oct4 directly regulates Pax7 expression by directly targeting its promoter, the promoter (Ϫ5001 to ϩ21) of Pax7 was cloned into pGL3-basic to make a reporter construct, designated as Pax7-5.0k-luc. Through bioinformatic prediction (www.Genomatix.de), an Oct4-binding site (referred to as Octamer 4.7k) with a perfect consensus sequence was found at Ϫ4754ϳϪ4747, which was flanked by a Sox2 binding-site (Ϫ4725ϳϪ4715) (Fig. 5A) . This binding site arrangement is similar to that of other well-known Oct4-Sox2 target genes (1, 30, 36) . When cotransfected into C2C12 myoblasts, Oct4 repressed the activity of Pax7-5.0k promoter in a dose- dependent manner (Fig. 5B) . This result suggests that Oct4 can directly target the Pax7 promoter to repress its activity and that the Octamer 4.7k may play an important role in this repression.
To confirm the regulation of Pax7 expression by Oct4 in normal chromatin context as opposed to transient transfection, Pax7-5.0k-Luc was stably transfected into C2C12 and a clonal cell line (C2C12-Pax7-5.0k-luc) was established. Subsequently, these cells were stably transfected with PyCAG and PyCAG-Oct4, respectively, to test the regulation of the Pax7 promoter fragment by Oct4. Consistent with the transient transfection results, chromosome-integrated Pax7-5.0k-luc activity was repressed about 40 -80% by Oct4 (Fig. 5C ). These results indicate that Pax7 is a bona fide target of Oct4. It was of interest to know whether Nanog cooperated with Oct4 to regulate the expression of Pax7 and other myogenic genes. We found that Oct4 and Nanog cooperated with each other to repress MyoD promoter activity; however, this cooperation was not observed on Pax7 promoter (Fig. 5D) , suggesting differential requirement of Oct4 and Nanog for repressing different myogenic genes. Fig. 6 . Oct4 binds Pax7 promoter directly.
32 P-labeled oligonucleotide corresponding to the Octamer 4.7k site in the Pax7 was bound either by in vitro transcribed and translated Oct4 (A) protein or by 5 g nuclear extract (B) from P19 and 10T1/2 cells in 20 l binding buffer. Protein and DNA complexes were resolved on a 5% acrylamide low ionic gel containing 5% glycerol at 4°C for at least 3.5 h. Signals on the gels were viewed by autoradiography. Antibody (0.1 g) against Oct4 was included in the binding reaction to verify the identity of factors contained in the retarded bands on the gel. The specificity of DNA and protein binding was tested by adding 10 -100ϫ amount of unlabeled cold Octamer 4.7k DNA (Pax7) as specific competitor or DNA corresponding to GADPH coding region as nonspecific competitor. NE, nuclear extract. C: Oct4 and Nanog bind to the Octamer 4.7k in vivo. C2C12-Oct4-Py-Nanog myoblast chromatin was immunoprecipitated with anti-Oct4 and anti-Nanog antibodies and then subjected to PCR with primers amplifying Oct4 exon9, Octamer 4.7k, and Nanog promoter. The signal of exon 9 served as a negative control.
To investigate whether Octamer 4.7k can be bound by Oct4 directly, we performed electrophoretic mobility shift assays. Oct4 bound strongly to 32 P-labeled Octamer 4.7k DNA probe (Fig. 6A) . Complexes formed by Octamer 4.7k DNA and Oct4 were supershifted by an Oct4 antibody (lane 3 of Fig. 6, A and  B) , confirming that the observed shift was due to Oct4 binding. Furthermore, nuclear extract isolated from P19 cells shifted this probe strongly, but not those isolated from 10T1/2 cells (Fig. 6B) . The specificity of this binding was confirmed by including specific and nonspecific competitors in the reactions. Therefore, our results suggest that Oct4 represses Pax7 expression by targeting its promoter directly, at least on the Octamer 4.7k site. To further elucidate whether Octamer 4.7k was targeted by Oct4 and Nanog in vivo, antibodies against Oct4 and Nanog were used to pull down their complex with chromatin in a chromatin immunoprecipitation assay. We found that, in C2C12-Oct4-Py-Nanog myoblasts, both Oct4 and Nanog bound to the Octamer 4.7k site (Fig. 6C ) and the previously reported targeted site on Nanog promoter (20) .
Oct4 and Nanog enhance the pluripotency of C2C12 cells.
The above results demonstrated that Oct4 and Nanog can abolish myogenic differentiation and enhance ES cell marker expression. What remains unknown, however, is whether Oct4 and Nanog can enhance the pluripotency of C2C12 cells. To answer this question, both retrovirus (retro)-Py-control and Oct4-Py-Nanog cells were injected subcutaneously into the dorsal flank of NOD SCID mice to allow them to form teratomas. Teratomas formed by retro-Py-control cells consisted mostly of immature muscle in the form of sarcomas (Fig. 7A) . Mature muscles and adipose tissues as well as vascular tissue were also found flanking the sarcoma tissues (Fig. 7B) . Teratomas formed by Oct4-Py-Nanog cells also consisted of immature muscle in the form of sarcoma (Fig. 7, C and D) . However, the percentage of mature muscles and adipose tissues was significantly increased (Fig. 7E) . In addition to these tissues also found with control cells, hair follicles formed in Oct4-Py-Nanog teratomas (Fig.  7F ). These observations suggest that overexpression of Oct4 and Nanog has enhanced the pluripotency of C2C12 cells. Fig. 7 . Teratomas formed by Retro-Py and Oct4-Py-Nanog cells. C2C12-retro-Py and C2C12-Oct4-Py-Nanog cells were injected subcutaneously into nonobese diabetic (NOD) severe combined immunodeficiency (SCID) mice to test their ability to form teratoma. Teratomas formed after 8 wk were fixed, dehydrated, embedded in paraffin, and sectioned at 2-to 5-m thickness. Sections were stained with hematoxylin-eosin. Representative tissue types in teratomas formed by Retro-Py (A and B) and Oct4-Py-Nanog (C-F) cells were photographed at ϫ100 magnification and are shown here. SR, sarcoma; M, muscle; AD, adipose tissue; V, vascular tissue; HF, hair follicle.
DISCUSSION
Before the discovery that overexpression of Msx1 could reverse C2C12 terminal differentiation from multinucleated myotubes back to mononucleated myoblasts, it was well accepted that terminal myogenic differentiation was irreversible. However, successful dedifferentiation of myotubes by Msx1 proved that manipulating the differentiation state of myogenic cells is a plausible approach to obtain myogenic cells in various stages of differentiation. However, the possibility of deriving stem cells or cells of other germ layers from myogenic cells has not been tested to date. If successful, this technology could be beneficial to regenerative medicine in the future. Therefore, we overexpressed the stem cell-specific transcription factors Oct4 and Nanog in C2C12 myoblasts to test the possibility of reversing their state of differentiation.
Surprisingly, the expression of Oct4 and Nanog in Sol8 cells was much higher than that in C2C12 myoblasts. Some cells in the C2C12 myoblast population have been found to possess stem cell-like properties and are believed to give rise to cells in different stages of differentiation (33) . The expression of Oct4 and Nanog in these stem cells (referred to as reserve cells) has not been examined thus far. If Oct4 and Nanog were expressed in reserve cells, as in other tissue-specific stem cells, their low expression in C2C12 might be explained by the low number of reserve cells in the C2C12 population. On the contrary, their high expression in Sol8 cells might represent a higher expression level in reserve cells or higher number of reserve cells in Sol8 cells. We have isolated reserve cells from these two cell lines, and further study is needed to examine their expression of Oct4 and Nanog.
Both Pax3 and Pax7 are expressed in myogenic precursors in the dermomyotome (10) . However, only Pax7 is involved in the proliferation/maintenance of satellite cells. The number of satellite cells in Pax7-null mice is significantly reduced, and they have a deficiency in postnatal skeletal muscle growth (24) . Therefore, Pax7 is a very important specification marker of myogenic stem cells in the dermomyotome and postnatal muscle. In our study, we found that Pax7 expression is very sensitive to the presence of Oct4; all Oct4 overexpressing clones lost Pax7 expression. Direct binding of Oct4 to the Pax7 promoter was demonstrated to occur at the Octamer 4.7k site. These observations suggest that one of the mechanisms of maintaining pluripotency by Oct4 is to repress or prevent the expression of early lineage-specific genes, such as Pax7. The repression of lineage-specific determination genes, such as MRFs, might need the cooperation of Oct4 and Nanog. It will be interesting to know whether these two factors need the facilitation of corepressors, such as NcoR, SMRT, Groucho, and CtBP, to repress target gene expression.
It has been shown that the effect of Oct4 expression is dose dependent: high expression levels drive ES cells into endoderm and mesoderm lineages, while low levels drive ES cells to trophectoderm. Only proper endogenous levels of Oct4 can retain ES cells in a pluripotent state (15) . Oct4 expression levels in C2C12 stable clones are similar to that in P19 cells (data not shown). In our hands, exogenous levels of Oct4 repressed the expression of Mrfs, Pax7, and M-cadherin, suggesting that this level of Oct4 expression is proper to drive the dedifferentiation of myoblasts. In the future, promoters of different strength will be employed to drive the expression of Oct4 to examine the dose-dependent effects on myogenesis.
Recently, Oct4, Nanog and Sox2 were found to function in an intricate network that reinforced their expression levels in ES cells (6, 11) . In addition, a number of common genes were also targeted by these three factors (11) , including some developmentally important homeobox genes, such as Pax6, that remain inactive in ES cells (2) . In ES cells, both Oct4 and Nanog can modulate gene expression positively and negatively, thus allowing them to activate the expression of genes required for the maintenance of pluripotency, while repressing that of lineage-determination genes. In this study, we found that the expression of Pax7 was repressed by Oct4, but not by Nanog. Oct4 regulates the activity of both promoter fragments tested, Pax7-3.8k and Pax7-5.0k-luc, suggesting that multiple sites within the Pax7 promoter are targeted by Oct4. We further defined that the Octamer 4.7 site was bound directly by Oct4 and thus may play a strong role in the repression of Pax7. Similar observation has been found in human ES cells by Loh et al. (11) . They identified an Oct4-binding site ϳ126 kb upstream of the Pax7 transcription initiation site, but evidence describing the regulation of human Pax7 expression by Oct4 is still lacking.
In contrast to Pax7, the transcriptional repression of Mrfs requires the cooperation of Oct4 and Nanog. Overexpression of Oct4 significantly reduced Mrf expression, which was further reduced by Nanog. It will be interesting to identify the molecular mechanism of how Oct4 and Nanog interact with each other to repress lineage-specific genes such as MyoD expression. There are many open questions regarding the mechanisms of Oct4-and Nanog-mediated gene repression. Are the corepressors recruited by Oct4 and Nanog to the promoter the same? Do they share the same corepressor complex? These are questions that need to be addressed. Apart from direct binding to target gene promoter, Nanog can also block bone morphogenetic protein-induced mesodermal differentiation by physically interacting with Smad1 and interfering with the recruitment of coactivators (26) . Whether the same/similar mechanisms are employed to the repression of myogenic genes remains to be determined.
Recently, three groups have reported that both mouse and human somatic cells can be induced to become pluripotent stem cells (iPS cell) by overexpressing defined factors that include Oct4, Nanog, Sox2, Klf4, and c-Myc or LIN28 (18, 27, 28, 32, 34) . These iPS cells are competent at forming most tissues and are germ-line competent if selected with Nanog expression. However, overexpression of c-Myc promoted tumorigenesis and thus should be avoided. These studies have confirmed our hypothesis that expression of stem cell pluripotent factors can reverse or induce somatic cells to pluripotent stage. In this study, we found that Klf4 was abundantly expressed in myoblasts and that the expression of Sox2 can be induced by Oct4 and Nanog. These results suggest that ES gene expression program can be induced by the simultaneous expression of Oct4 and Nanog in C2C12 myoblast cell line. If the positive feedback loop of MRFs can be blocked completely, then the myogenic expression program can be totally removed and these cells can be reversed back to pluripotent stage. We are currently adjusting our culture system to block myogenic positive feedback loop and are adopting ES culture system to create pluripotent C2C12-Oct4-Py-Nanog cells (unpublished observations).
